| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥195.71B | ¥195.07B | +0.3% |
| Cost of Sales | ¥139.42B | ¥141.14B | -1.2% |
| Gross Profit | ¥56.29B | ¥53.93B | +4.4% |
| SG&A Expenses | ¥36.53B | ¥35.64B | +2.5% |
| Operating Income | ¥19.77B | ¥18.30B | +8.0% |
| Non-operating Income | ¥3.62B | ¥3.10B | +16.8% |
| Non-operating Expenses | ¥3.39B | ¥4.53B | -25.2% |
| Ordinary Income | ¥20.00B | ¥16.87B | +18.6% |
| Profit Before Tax | ¥20.31B | ¥16.72B | +21.5% |
| Income Tax Expense | ¥6.17B | ¥4.75B | +29.9% |
| Net Income | ¥14.14B | ¥11.97B | +18.1% |
| Net Income Attributable to Owners | ¥12.42B | ¥11.48B | +8.1% |
| Total Comprehensive Income | ¥20.38B | ¥8.96B | +127.5% |
| Depreciation & Amortization | ¥9.06B | ¥8.78B | +3.2% |
| Interest Expense | ¥1.62B | ¥1.68B | -3.2% |
| Basic EPS | ¥122.39 | ¥112.55 | +8.7% |
| Dividend Per Share | ¥48.00 | ¥48.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥347.21B | ¥349.89B | ¥-2.68B |
| Cash and Deposits | ¥113.44B | ¥110.12B | +¥3.32B |
| Accounts Receivable | ¥91.97B | ¥110.06B | ¥-18.08B |
| Inventories | ¥68.58B | ¥61.51B | +¥7.07B |
| Non-current Assets | ¥195.15B | ¥193.23B | +¥1.92B |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥31.29B | ¥33.00B | ¥-1.72B |
| Investing Cash Flow | ¥-21.56B | ¥-9.44B | ¥-12.12B |
| Financing Cash Flow | ¥-17.33B | ¥-17.08B | ¥-256M |
| Free Cash Flow | ¥9.73B | - | - |
| Item | Value |
|---|---|
| Net Profit Margin | 6.3% |
| Gross Profit Margin | 28.8% |
| Current Ratio | 311.2% |
| Quick Ratio | 249.7% |
| Debt-to-Equity Ratio | 0.51x |
| Interest Coverage Ratio | 12.18x |
| EBITDA Margin | 14.7% |
| Effective Tax Rate | 30.4% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +0.3% |
| Operating Income YoY Change | +8.0% |
| Ordinary Income YoY Change | +18.6% |
| Net Income Attributable to Owners YoY Change | +8.1% |
| Total Comprehensive Income YoY Change | +127.5% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 103.77M shares |
| Treasury Stock | 3.38M shares |
| Average Shares Outstanding | 101.48M shares |
| Book Value Per Share | ¥3,582.24 |
| EBITDA | ¥28.82B |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥48.00 |
| Year-End Dividend | ¥52.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| Chemicals | ¥104.97B | ¥13.04B |
| FoodProducts | ¥40.69B | ¥2.07B |
| LifeSciences | ¥47.71B | ¥4.16B |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥441.00B |
| Operating Income Forecast | ¥43.00B |
| Ordinary Income Forecast | ¥43.00B |
| Net Income Attributable to Owners Forecast | ¥26.40B |
| Basic EPS Forecast | ¥262.97 |
| Dividend Per Share Forecast | ¥52.00 |
| Property, Plant & Equipment | ¥124.61B | ¥125.87B | ¥-1.26B |
| Intangible Assets | ¥15.58B | ¥14.64B | +¥933M |
| Investment Securities | ¥45.63B | ¥42.80B | +¥2.82B |
| Total Assets | ¥542.36B | ¥543.12B | ¥-759M |
| Current Liabilities | ¥111.59B | ¥122.24B | ¥-10.66B |
| Accounts Payable | ¥58.26B | ¥60.21B | ¥-1.96B |
| Short-term Loans | ¥16.87B | ¥18.55B | ¥-1.68B |
| Non-current Liabilities | ¥71.14B | ¥69.10B | +¥2.04B |
| Long-term Loans | ¥26.72B | ¥26.14B | +¥577M |
| Total Liabilities | ¥182.73B | ¥191.34B | ¥-8.62B |
| Total Equity | ¥359.63B | ¥351.78B | +¥7.86B |
| Capital Stock | ¥23.05B | ¥23.05B | ¥0 |
| Capital Surplus | ¥20.46B | ¥20.35B | +¥115M |
| Retained Earnings | ¥235.12B | ¥228.11B | +¥7.01B |
| Treasury Stock | ¥-9.09B | ¥-4.67B | ¥-4.42B |
| Owners' Equity | ¥305.21B | ¥296.69B | +¥8.52B |
| Working Capital | ¥235.62B | - | - |